1Walmsleys, TsengA. Comparative tolerability of therapies for cytomegalovirus retinitis. Drug Safety, 1999, 21 (3):203.
2Chatelain E , Deminiere C, Lacut JY, et al. Severe renal failure and polyneuritis induced by foscarnet. Nephrology Dialysis Transplantation, 1998, 13: 2368.
3Zaman MM, Burney S, Landman D, et al. Rapid development of renal insufficiency with the simultaneous administration of amphotericin B and foscarnet. Clinical Infectious Diseases, 1996, 22 (5): 378.
4Nyberg G, Blohme I, Persson H, et al. Foscarnet - induced tubulointerstitial nephritis in renal transplant patients. Transplantation Proceedings, 1990, 22: 241.
5Trolliet P, Dijoud F, Gotte L, et al. Crescentic glomerulonephritis and crystals within glomerular capillaries in an AIDS patient treated with foscarnet. Am J Nephrol ,1995, 15: 256-259.
6Navarro JF, Quereda C, Moreno A, et al. Renal tubular acidosis following treatment with foscarnet. AIDS, 1995,9: 1389- 1390.
7Tarese Jr RV, Schambelan M, Hollander H, et al.Nephrogenic diabetes insipidus associated with foscamet treatment of cytomegalovirus retinitis. Annals of Internal Medicine, 1990, 112: 955-956.
8Deray G, Katlama C, Dohin E, et al. Prevention of foscarnet nephrotoxicity. Annals of Internal Medicine, 1990,113: 332.
9Deray G, Martinez F, Katlama C, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol, 1989, 9: 316.
